TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Torrent Pharmaceuticals Ltd.

TORNTPHARM on NSE · 19 Nov 2026

NIFTY 500 F&O

4,611.00 ▲ +0.01 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
23 Oct 2026Legal or regulatoryTorrent Pharmaceuticals' board approved the audited standalone and unaudited consolidated financial results for the quarter and half year ended 30 September 2026 at a meeting held on 23 October 2026. The standalone results include the financials of erstwhile J. B. Chemicals & Pharmaceuticals Limited (JBCPL), merged... NSE copy
07 Oct 2026Credit ratingTorrent Pharmaceuticals intimated under Regulation 30 of SEBI LODR that India Ratings and Research Private Limited affirmed the credit rating and revised the outlook from stable to positive for the Company's existing banking facilities, issuer rating and Non-Convertible Debentures, with rating IND AA+/Positive.... NSE copy
30 Jul 2026Management changeBoard of Torrent Pharmaceuticals approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026, with limited review report; board meeting ran 2:00 pm to 4:40 pm. Filing encloses a press release on the financial results (Annexure B); the figures themselves are not in the pages... NSE copy
05 Jan 2026Credit ratingTorrent Pharmaceuticals Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations, 2015, dated 05 January 2026, about a credit rating action by ICRA Limited. ICRA reaffirmed the long-term rating of the company's banking facilities and Non-Convertible Debentures (NCDs) at [ICRA] AA+ (Stable). ICRA... NSE copy
02 Jan 2026Credit ratingTorrent Pharmaceuticals Limited filed intimation under Regulation 30 of SEBI LODR regarding a credit rating from India Ratings and Research Private Limited. India Ratings affirmed the rating of the Company's existing banking facilities, issuer rating and Non-Convertible Debentures (NCDs) at IND AA+(Stable). India... NSE copy
07 Oct 2025Credit ratingTorrent Pharmaceuticals Limited filed an intimation of credit ratings from ICRA Limited under Regulation 30 of SEBI LODR, dated 7 October 2025. ICRA reaffirmed the long-term rating of the banking facilities and existing NCDs at [ICRA] AA+ (Stable). ICRA assigned a rating of [ICRA] AA+ (Stable) to the proposed NCDs... NSE copy
07 Oct 2025Credit ratingTorrent Pharmaceuticals Limited intimated under Regulation 30 of SEBI LODR that India Ratings and Research Private Limited has affirmed the credit rating of the Company's existing banking facilities, issuer rating and Non-Convertible Debentures (NCDs). India Ratings and Research also assigned a credit rating to the... NSE copy
30 Jun 2025Legal or regulatoryTorrent Pharmaceuticals filed an investor presentation on its acquisition of a controlling stake in JB Chemicals & Pharmaceuticals. The SPA covers a 46.39% equity stake (fully diluted) at INR 11,917 crores (INR 1,600 per share), which triggers a mandatory open offer for up to 26% at INR 1,639.18 per share. Torrent... NSE copy
29 Jun 2025Legal or regulatoryTorrent Pharmaceuticals' board approved, on 29 June 2025, the acquisition of 7,44,81,519 equity shares (46.39% fully diluted) of J.B. Chemicals & Pharmaceuticals from promoter Tau Investment Holdings at INR 1,600 per share, for a total consideration of about INR 11,917 crore in cash. The board also approved a... NSE copy
20 May 2025Management changeBoard of Torrent Pharmaceuticals approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with unmodified audit reports, and a press release on the results was attached. Board recommended a final dividend of ₹6 per equity share (120%) of face value ₹5, with record... NSE copy
20 May 2025Management changeTorrent Pharmaceuticals' board, meeting held on 20 May 2025, approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with unmodified audit opinions. The board recommended a final dividend of ₹6 per equity share (120%) on shares of ₹5 each, to be paid on or around... NSE copy
20 May 2025Management changeBoard of Torrent Pharmaceuticals approved audited standalone and consolidated financial results for the quarter and year ended 31 March 2025, with unmodified audit reports; a press release on the results is attached. Board recommended a final dividend of ₹6 per equity share (120%) of ₹5 each, record date 20 June... NSE copy
19 Mar 2025Credit ratingTorrent Pharmaceuticals Limited intimated under Regulation 30 of SEBI LODR that ICRA Limited reaffirmed the long-term credit rating of its banking facilities and non-convertible debentures at [ICRA] AA+ (Stable). ICRA Limited reaffirmed the rating for the existing amount of the commercial paper programme at [ICRA]... NSE copy
24 Jan 2025Management changeTorrent Pharmaceuticals filed intimation under Regulation 30 of the SEBI Listing Regulations after its board meeting held on 24 January 2025. The board approved audited standalone and unaudited consolidated financial results for the quarter and nine months ended 31 December 2024, and a press release on the results... NSE copy
24 Jan 2025Management changeTorrent Pharmaceuticals filed intimation of Board meeting outcome held on 24 January 2025, approving audited standalone and unaudited consolidated financial results for the quarter and nine months ended 31 December 2024. The Board approved an interim dividend of ₹26 per equity share (520%) on a face value of ₹5,... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (15 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in